Home > Product Overview > Furaprevir

Hepatitis C virus protease inhibitor Furaprevir

World-wide estimates put the number infected with hepatitis C virus (HCV) at over 170 million. There are about one quarter of HCV patients in Greater China and about ten million of HCV patients in China. The market size and medical needs is large because of low screening rate, low consultation rate and high incidence.

With conventional HCV therapy, patients must suffer through the drugs' many side effects, including flu-like symptoms, fatigue and anemia. Current oral antiviral medication is too expensive to afford; the entrance of new drug will provide reasonable and affordable price to patients.

Furaprevir is a HCV protease inhibitor, discovered and developed in-house by TaiGen’s researchers. Through careful rational drug design with over 1,500 compounds synthesized and after extensive screening, Furaprevir was chosen for further development. Furaprevir has completed Phase I/II clinical trials in Taiwan under an US IND.

TaiGen Biopharmaceuticals Co. (Beijing), Ltd. has signed an agreement with YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (“HEC”) to establish a new company in mainland China for the joint development, manufacturing and commercialization of direct-acting antiviral agents (DAAs) for all-oral interferon-free treatment of chronic hepatitis C virus infection in the Greater China region (mainland China, Taiwan, Hong Kong and Macau). A combo treatment with Furaprevir and Yimitasvir has completed the treatment of Phase II clinical trial and will initiate Phase III trial in 2019.

Market positioning and competitive advantage

All-oral antiviral drug focus on multi-genotype and with high efficacy, interferon-free, minimal side effect, short treatment course and affordable price.

Once-a-day oral dosing, without the need of interferon as a combination

Furaprevir is effective on HCV genotypes 1 through 6.

The combination of Furaprevir and Yimitasvir enhance antiviral activity and suppress drug-resistant HCV variants.

Furaprevir has a direct effect on HCV NS3/4A protease, blocking the viral polyprotein from being cleaved into the active protein, thereby inhibiting the replication of the virus gene. RNA viral replication pathway is shown.